1
|
Smith K, Deutsch AJ, McGrail C, Kim H, Hsu S, Huerta-Chagoya A, Mandla R, Schroeder PH, Westerman KE, Szczerbinski L, Majarian TD, Kaur V, Williamson A, Zaitlen N, Claussnitzer M, Florez JC, Manning AK, Mercader JM, Gaulton KJ, Udler MS. Multi-ancestry polygenic mechanisms of type 2 diabetes. Nat Med 2024; 30:1065-1074. [PMID: 38443691 DOI: 10.1038/s41591-024-02865-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2023] [Accepted: 02/06/2024] [Indexed: 03/07/2024]
Abstract
Type 2 diabetes (T2D) is a multifactorial disease with substantial genetic risk, for which the underlying biological mechanisms are not fully understood. In this study, we identified multi-ancestry T2D genetic clusters by analyzing genetic data from diverse populations in 37 published T2D genome-wide association studies representing more than 1.4 million individuals. We implemented soft clustering with 650 T2D-associated genetic variants and 110 T2D-related traits, capturing known and novel T2D clusters with distinct cardiometabolic trait associations across two independent biobanks representing diverse genetic ancestral populations (African, n = 21,906; Admixed American, n = 14,410; East Asian, n =2,422; European, n = 90,093; and South Asian, n = 1,262). The 12 genetic clusters were enriched for specific single-cell regulatory regions. Several of the polygenic scores derived from the clusters differed in distribution among ancestry groups, including a significantly higher proportion of lipodystrophy-related polygenic risk in East Asian ancestry. T2D risk was equivalent at a body mass index (BMI) of 30 kg m-2 in the European subpopulation and 24.2 (22.9-25.5) kg m-2 in the East Asian subpopulation; after adjusting for cluster-specific genetic risk, the equivalent BMI threshold increased to 28.5 (27.1-30.0) kg m-2 in the East Asian group. Thus, these multi-ancestry T2D genetic clusters encompass a broader range of biological mechanisms and provide preliminary insights to explain ancestry-associated differences in T2D risk profiles.
Collapse
Affiliation(s)
- Kirk Smith
- Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Aaron J Deutsch
- Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Medicine, Harvard Medical School, Boston, MA, USA
| | - Carolyn McGrail
- Biomedical Sciences Graduate Program, University of California, San Diego, La Jolla, CA, USA
| | - Hyunkyung Kim
- Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Committee on Genetics, Genomics and Systems Biology, University of Chicago, Chicago, IL, USA
- Section of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, IL, USA
| | - Sarah Hsu
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA
| | - Alicia Huerta-Chagoya
- Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Ravi Mandla
- Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Philip H Schroeder
- Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Kenneth E Westerman
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Medicine, Harvard Medical School, Boston, MA, USA
- Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA
| | - Lukasz Szczerbinski
- Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland
- Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland
| | - Timothy D Majarian
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA
- Vertex Pharmaceuticals, Boston, MA, USA
| | - Varinderpal Kaur
- Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Alice Williamson
- Precision Healthcare University Research Institute, Queen Mary University of London, London, UK
- MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK
| | - Noah Zaitlen
- Department of Neurology, University of California, Los Angeles, Los Angeles, CA, USA
- Department of Computational Medicine, University of California, Los Angeles, Los Angeles, CA, USA
- Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA
| | - Melina Claussnitzer
- Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Medicine, Harvard Medical School, Boston, MA, USA
- Novo Nordisk Foundation Center for Genomic Mechanisms of Disease, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Jose C Florez
- Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Medicine, Harvard Medical School, Boston, MA, USA
| | - Alisa K Manning
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Medicine, Harvard Medical School, Boston, MA, USA
- Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA
| | - Josep M Mercader
- Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Medicine, Harvard Medical School, Boston, MA, USA
| | - Kyle J Gaulton
- Department of Pediatrics, University of California, San Diego, San Diego, CA, USA
| | - Miriam S Udler
- Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
- Department of Medicine, Harvard Medical School, Boston, MA, USA.
| |
Collapse
|
2
|
Onuoha C, Schulte CCM, Thaweethai T, Hsu S, Pant D, James KE, Sen S, Kaimal A, Powe CE. The simultaneous occurrence of gestational diabetes and hypertensive disorders of pregnancy affects fetal growth and neonatal morbidity. Am J Obstet Gynecol 2024:S0002-9378(24)00438-1. [PMID: 38492713 DOI: 10.1016/j.ajog.2024.03.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2023] [Revised: 02/04/2024] [Accepted: 03/08/2024] [Indexed: 03/18/2024]
Abstract
BACKGROUND Gestational diabetes is associated with increased risk of hypertensive disorders of pregnancy, but there are limited data on fetal growth and neonatal outcomes when both conditions are present. OBJECTIVE We evaluated the risk of abnormal fetal growth and neonatal morbidity in pregnancies with co-occurrence of gestational diabetes and hypertensive disorders of pregnancy. STUDY DESIGN In a retrospective study of 47,093 singleton pregnancies, we compared the incidence of appropriate for gestational age birthweight in pregnancies affected by gestational diabetes alone, hypertensive disorders of pregnancy alone, or both gestational diabetes and hypertensive disorders of pregnancy with that in pregnancies affected by neither disorder using generalized estimating equations (covariates: maternal age, nulliparity, body mass index, insurance type, race, marital status, and prenatal care site). Secondary outcomes were large for gestational age birthweight, small for gestational age birthweight, and a neonatal morbidity composite outcome (stillbirth, hypoglycemia, hyperbilirubinemia, respiratory distress, encephalopathy, preterm delivery, neonatal death, and neonatal intensive care unit admission). RESULTS The median (interquartile range) birthweight percentile in pregnancies with both gestational diabetes and hypertensive disorders of pregnancy (50 [24.0-78.0]; N=179) was similar to that of unaffected pregnancies (50 [27.0-73.0]; N=35,833). However, the absolute rate of appropriate for gestational age birthweight was lower for gestational diabetes/hypertensive disorders of pregnancy co-occurrence (78.2% vs 84.9% for unaffected pregnancies). Adjusted analyses showed decreased odds of appropriate for gestational age birthweight in pregnancies with both gestational diabetes and hypertensive disorders of pregnancy compared with unaffected pregnancies (adjusted odds ratio, 0.72 [95% confidence interval, 0.52-1.00]; P=.049), and in pregnancies complicated by gestational diabetes alone (adjusted odds ratio, 0.78 [0.68-0.89]; P<.001) or hypertensive disorders of pregnancy alone (adjusted odds ratio, 0.73 [0.66-0.81]; P<.001). The absolute risk of large for gestational age birthweight was greater in pregnancies with both gestational diabetes and hypertensive disorders of pregnancy (14.5%) than in unaffected pregnancies (8.2%), without apparent difference in the risk of small for gestational age birthweight (7.3% vs 6.9%). However, in adjusted models comparing pregnancies with gestational diabetes/hypertensive disorders of pregnancy co-occurrence with unaffected pregnancies, neither an association with large for gestational age birthweight (adjusted odds ratio, 1.33 [0.88-2.00]; P=.171) nor small for gestational age birthweight (adjusted odds ratio, 1.32 [0.80-2.19]; P=.293) reached statistical significance. Gestational diabetes/hypertensive disorders of pregnancy co-occurrence carried an increased risk of neonatal morbidity that was greater than that observed with either condition alone (gestational diabetes/hypertensive disorders of pregnancy: adjusted odds ratio, 3.13 [2.35-4.17]; P<.001; gestational diabetes alone: adjusted odds ratio, 2.01 [1.78-2.27]; P<.001; hypertensive disorders of pregnancy alone: adjusted odds ratio, 1.38 [1.26-1.50]; P<.001). CONCLUSION Although pregnancies with both gestational diabetes and hypertensive disorders of pregnancy have a similar median birthweight percentile to those affected by neither condition, pregnancies concurrently affected by both conditions have a higher risk of abnormal fetal growth and neonatal morbidity.
Collapse
Affiliation(s)
- Chioma Onuoha
- School of Medicine, University of California, San Francisco, San Francisco, CA
| | | | - Tanayott Thaweethai
- Biostatistics Center, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - Sarah Hsu
- Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA
| | - Deepti Pant
- Biostatistics Center, Massachusetts General Hospital, Boston, MA
| | - Kaitlyn E James
- Harvard Medical School, Boston, MA; Department of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
| | - Sarbattama Sen
- Harvard Medical School, Boston, MA; Department of Pediatrics, Brigham and Women's Hospital, Boston, MA
| | - Anjali Kaimal
- Department of Obstetrics and Gynecology, University of South Florida Morsani College of Medicine, Tampa, FL
| | - Camille E Powe
- Harvard Medical School, Boston, MA; Broad Institute, Cambridge, MA; Diabetes Unit, Endocrinology Division, Massachusetts General Hospital, Boston, MA.
| |
Collapse
|
3
|
Smith K, Deutsch AJ, McGrail C, Kim H, Hsu S, Mandla R, Schroeder PH, Westerman KE, Szczerbinski L, Majarian TD, Kaur V, Williamson A, Claussnitzer M, Florez JC, Manning AK, Mercader JM, Gaulton KJ, Udler MS. Multi-ancestry Polygenic Mechanisms of Type 2 Diabetes Elucidate Disease Processes and Clinical Heterogeneity. Res Sq 2023:rs.3.rs-3399145. [PMID: 37886436 PMCID: PMC10602111 DOI: 10.21203/rs.3.rs-3399145/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2023]
Abstract
We identified genetic subtypes of type 2 diabetes (T2D) by analyzing genetic data from diverse groups, including non-European populations. We implemented soft clustering with 650 T2D-associated genetic variants, capturing known and novel T2D subtypes with distinct cardiometabolic trait associations. The twelve genetic clusters were distinctively enriched for single-cell regulatory regions. Polygenic scores derived from the clusters differed in distribution between ancestry groups, including a significantly higher proportion of lipodystrophy-related polygenic risk in East Asian ancestry. T2D risk was equivalent at a BMI of 30 kg/m2 in the European subpopulation and 24.2 (22.9-25.5) kg/m2 in the East Asian subpopulation; after adjusting for cluster-specific genetic risk, the equivalent BMI threshold increased to 28.5 (27.1-30.0) kg/m2 in the East Asian group, explaining about 75% of the difference in BMI thresholds. Thus, these multi-ancestry T2D genetic subtypes encompass a broader range of biological mechanisms and help explain ancestry-associated differences in T2D risk profiles.
Collapse
Affiliation(s)
- Kirk Smith
- Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Aaron J. Deutsch
- Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Medicine, Harvard Medical School, Boston, MA, USA
| | - Carolyn McGrail
- Department of Pediatrics, University of California San Diego, San Diego, CA, USA
| | - Hyunkyung Kim
- Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Committee on Genetics, Genomics and Systems Biology, University of Chicago, Chicago, IL, USA
- Section of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, IL, USA
| | - Sarah Hsu
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA
| | - Ravi Mandla
- Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Philip H. Schroeder
- Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Kenneth E. Westerman
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Medicine, Harvard Medical School, Boston, MA, USA
- Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA
| | - Lukasz Szczerbinski
- Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland
- Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland
| | - Timothy D. Majarian
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA
| | - Varinderpal Kaur
- Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Alice Williamson
- Precision Healthcare University Research Institute, Queen Mary University of London, London, UK
- MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK
| | - Melina Claussnitzer
- Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Medicine, Harvard Medical School, Boston, MA, USA
- The Novo Nordisk Foundation Center for Genomic Mechanisms of Disease, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Jose C. Florez
- Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Medicine, Harvard Medical School, Boston, MA, USA
| | - Alisa K. Manning
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Medicine, Harvard Medical School, Boston, MA, USA
- Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA
| | - Josep M. Mercader
- Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Medicine, Harvard Medical School, Boston, MA, USA
| | - Kyle J. Gaulton
- Department of Pediatrics, University of California San Diego, San Diego, CA, USA
| | - Miriam S. Udler
- Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Medicine, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
4
|
Ku ECY, Hsu S, Banker R, Healy E, Chen AM, Harris JP. Pre- and Post-Treatment Patient-Reported Financial Toxicity in Head and Neck Cancer: Identifying Influential Factors and Clinical Significance. Int J Radiat Oncol Biol Phys 2023; 117:e241-e242. [PMID: 37784951 DOI: 10.1016/j.ijrobp.2023.06.1170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Head and neck cancer patients are at high-risk for financial stress due to the often complex, time-consuming, and expensive treatments that can impact physical function and quality of life. It is important to identify factors that affect financial toxicity early on in treatment and to help mitigate their effects. The goals of this study are to assess patient-reported financial toxicity prior to and after completion of radiation therapy (RT) and to uncover any interactions with socioeconomic factors, quality of life, treatment satisfaction, and treatment adherence. MATERIALS/METHODS A total of 80 patients who were evaluated for RT to the head and neck region between July 2021 and December 2022 and had completed surveys prior to the initiation of RT were included. Surveys included the FACIT-COST and FACIT-TS-G. Patient clinical information and demographics were collected. Linear regression was used to evaluate categorical variables and Pearson correlation was used to evaluate continuous variables and their associations with COST. RESULTS The median pre-RT COST was 29.5 (range 4-44) with lower scores indicating worse financial toxicity. The majority of patients were white (69%), non-Hispanic (75%), and English-speaking (75%). 65% had Medicare, 14% had Medicaid, and 21% had other insurance. 60 of 80 (75%) patients ultimately underwent RT at our institution. 34 (57%) missed at least one day of scheduled RT fractions and 11 (14%) patients had G-tubes placed. Lower COST was associated with decreased age, thyroid primary disease, advanced stage, metastatic disease, Medicaid insurance, Hispanic ethnicity, unemployment, and G-tube placement. Higher COST was associated with cutaneous primary disease and ability to speak English, while Medicare insurance trended toward significance. 18 of 80 patients (23%) completed follow-up surveys post-RT and 9 reported a decrease in COST. At baseline, the standard deviation of the COST was 10.6. Effect size was defined as the number of standard deviation change. Mean decrease in COST was 9.4 (effect size of 89%). Mean FACT-TS-G was lower, indicating decreased treatment satisfaction, for these patients as compared to those that had the same or increased COST compared to baseline, (17.4 vs. 22.7, p < 0.01). There were more missed RT days, 4 vs. 1, and G-tube placements, 2 vs. 0, in those with decreased COST as well. CONCLUSION Worse baseline financial toxicity was associated with younger age, advanced stage, metastatic disease, Medicaid insurance, unemployment, and G-tube placement. Those that reported worsened financial toxicity after RT reported worse treatment satisfaction and had more missed RT days and G-tube placements. These findings support work to better understand financial toxicity as it may predict those at higher risk of missing treatments, particularly crucial considering prolonged RT duration is linked to poorer outcomes. Future efforts will focus on automating early referrals to case managers and social work services for these patients.
Collapse
Affiliation(s)
- E C Y Ku
- Department of Radiation Oncology, University of California - Irvine, Orange, CA
| | - S Hsu
- Department of Radiation Oncology, University of California - Irvine, Orange, CA
| | - R Banker
- Department of Hematology/Oncology, University of California Irvine - Orange, CA, Orange, CA
| | - E Healy
- Department of Radiation Oncology, University of California - Irvine, Orange, CA
| | - A M Chen
- Department of Radiation Oncology, University of California - Irvine, Orange, CA
| | - J P Harris
- Department of Radiation Oncology, University of California - Irvine, Orange, CA
| |
Collapse
|
5
|
Harris JP, Hsu S, Ku ECY, Nagasaka M, Kuo JV, Healy E. Severity of Financial Toxicity for Patients Receiving Palliative Radiation Therapy. Int J Radiat Oncol Biol Phys 2023; 117:e234-e235. [PMID: 37784933 DOI: 10.1016/j.ijrobp.2023.06.1153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Patients receiving palliative radiotherapy (RT) are often at their most vulnerable state, but the impact of financial toxicity on their health and quality of life (QOL) is not well-described. We set out to determine the degree of financial toxicity in a population undergoing palliative RT. MATERIALS/METHODS A review of patients referred for palliative RT at our site was conducted. Financial toxicity was determined with COST-FACIT, and previously suggested grading cutoffs were used. Additional patient-reported outcome (PRO) instruments included the EORTC overall health and quality of life questions and the FACIT-TS-G (treatment satisfaction). Multiple imputations by chained equations using predictive mean matching were used for incomplete responses. Spearman's rank correlation coefficient, Kruskal-Wallis testing, and linear regressions were used to measure associations. RESULTS A total of 53 patients were identified who had completed PRO surveys between May 2021 and December 2022. Median COST was 25 (range 0-44), with lower scores indicating greater financial toxicity. 49% reported grade 0 financial toxicity (COST ≥26), 32% had grade 1 financial toxicity (COST 14-25), 19% had grade 2 financial toxicity (COST 1-13), and 6% had grade 3 financial toxicity (COST = 0). Overall, cancer caused financial hardship among 45%. Higher COST was moderately associated with higher overall health (rho = 0.36, p = 0.02) and weakly associated with higher QOL (rho = 0.28, p = 0.07). From a demographic standpoint, median area family income from census tract data was $98,598 (range $32,303-$190,833), and higher income was associated with higher COST (rho = 0.47, p<0.001). Having Medicare (beta = 13.8, p = 0.003) or private (beta = 13.5, p = 0.001) coverage (rather than Medicaid) were associated with less financial toxicity, whereas having an underrepresented minority background (beta = -13.2, p<0.001), or having a non-English language preference (rho = 0.40, p = 0.003) were associated with greater financial toxicity. Median time from diagnosis was 12.9 mo, and 40% of patients had ≥2 prior systemic therapies. The median RT dose was 25 Gy (range 4-45 Gy). The most common irradiated sites included spine (24%), non-spine bones (21%), brain (18%), and lung/mediastinum (18%). COST was not associated with number of prior systemic therapies (p = 0.31), RT dose (p = 0.83), RT technique (p = 0.86), or treatment satisfaction (p = 0.34). Median follow up was 8.0 months, and median 6-month survival was 83% (95% CI 73%-95%). Inferior OS was associated with more prior systemic therapies (HR 3.43, p = 0.03), but not with COST (HR 1.01, p = 0.67). CONCLUSION Financial toxicity was seen in approximately half of patients receiving palliative RT. Patient-reported overall health, Medicaid coverage, and area income correlated well with financial toxicity, but the investigated clinical characteristics did not. This supports the hypothesis that financial toxicity is common and a unique factor that should be measured in cancer patients.
Collapse
Affiliation(s)
- J P Harris
- Department of Radiation Oncology, University of California - Irvine, Orange, CA
| | - S Hsu
- Department of Radiation Oncology, University of California - Irvine, Orange, CA
| | - E C Y Ku
- Department of Radiation Oncology, University of California - Irvine, Orange, CA
| | - M Nagasaka
- Division of Hematology and Oncology, University of California - Irvine, Orange, CA
| | - J V Kuo
- Department of Radiation Oncology, University of California - Irvine, Orange, CA
| | - E Healy
- Department of Radiation Oncology, University of California - Irvine, Orange, CA
| |
Collapse
|
6
|
Smith K, Deutsch AJ, McGrail C, Kim H, Hsu S, Mandla R, Schroeder PH, Westerman KE, Szczerbinski L, Majarian TD, Kaur V, Williamson A, Claussnitzer M, Florez JC, Manning AK, Mercader JM, Gaulton KJ, Udler MS. Multi-ancestry Polygenic Mechanisms of Type 2 Diabetes Elucidate Disease Processes and Clinical Heterogeneity. medRxiv 2023:2023.09.28.23296294. [PMID: 37808749 PMCID: PMC10557820 DOI: 10.1101/2023.09.28.23296294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/10/2023]
Abstract
We identified genetic subtypes of type 2 diabetes (T2D) by analyzing genetic data from diverse groups, including non-European populations. We implemented soft clustering with 650 T2D-associated genetic variants, capturing known and novel T2D subtypes with distinct cardiometabolic trait associations. The twelve genetic clusters were distinctively enriched for single-cell regulatory regions. Polygenic scores derived from the clusters differed in distribution between ancestry groups, including a significantly higher proportion of lipodystrophy-related polygenic risk in East Asian ancestry. T2D risk was equivalent at a BMI of 30 kg/m2 in the European subpopulation and 24.2 (22.9-25.5) kg/m2 in the East Asian subpopulation; after adjusting for cluster-specific genetic risk, the equivalent BMI threshold increased to 28.5 (27.1-30.0) kg/m2 in the East Asian group, explaining about 75% of the difference in BMI thresholds. Thus, these multi-ancestry T2D genetic subtypes encompass a broader range of biological mechanisms and help explain ancestry-associated differences in T2D risk profiles.
Collapse
Affiliation(s)
- Kirk Smith
- Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Aaron J. Deutsch
- Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Medicine, Harvard Medical School, Boston, MA, USA
| | - Carolyn McGrail
- Department of Pediatrics, University of California San Diego, San Diego, CA, USA
| | - Hyunkyung Kim
- Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Committee on Genetics, Genomics and Systems Biology, University of Chicago, Chicago, IL, USA
- Section of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, IL, USA
| | - Sarah Hsu
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA
| | - Ravi Mandla
- Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Philip H. Schroeder
- Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Kenneth E. Westerman
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Medicine, Harvard Medical School, Boston, MA, USA
- Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA
| | - Lukasz Szczerbinski
- Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland
- Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland
| | - Timothy D. Majarian
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA
| | - Varinderpal Kaur
- Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Alice Williamson
- Precision Healthcare University Research Institute, Queen Mary University of London, London, UK
- MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK
| | - Melina Claussnitzer
- Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Medicine, Harvard Medical School, Boston, MA, USA
- The Novo Nordisk Foundation Center for Genomic Mechanisms of Disease, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Jose C. Florez
- Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Medicine, Harvard Medical School, Boston, MA, USA
| | - Alisa K. Manning
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Medicine, Harvard Medical School, Boston, MA, USA
- Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA
| | - Josep M. Mercader
- Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Medicine, Harvard Medical School, Boston, MA, USA
| | - Kyle J. Gaulton
- Department of Pediatrics, University of California San Diego, San Diego, CA, USA
| | - Miriam S. Udler
- Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Medicine, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
7
|
Maya J, Selen DJ, Thaweethai T, Hsu S, Godbole D, Schulte CC, James K, Sen S, Kaimal A, Hivert MF, Powe CE. Gestational Glucose Intolerance and Birth Weight-Related Complications. Obstet Gynecol 2023; 142:594-602. [PMID: 37539973 PMCID: PMC10527009 DOI: 10.1097/aog.0000000000005278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2023] [Accepted: 04/13/2023] [Indexed: 08/05/2023]
Abstract
OBJECTIVE To evaluate the risks of large-for-gestational-age birth weight (LGA) and birth weight-related complications in pregnant individuals with gestational glucose intolerance, an abnormal screening glucose loading test result without meeting gestational diabetes mellitus (GDM) criteria. METHODS In a retrospective cohort study of 46,989 individuals with singleton pregnancies who delivered after 28 weeks of gestation, those with glucose loading test results less than 140 mg/dL were classified as having normal glucose tolerance. Those with glucose loading test results of 140 mg/dL or higher and fewer than two abnormal values on a 3-hour 100-g oral glucose tolerance test (OGTT) were classified as having gestational glucose intolerance. Those with two or more abnormal OGTT values were classified as having GDM. We hypothesized that gestational glucose intolerance would be associated with higher odds of LGA (birth weight greater than the 90th percentile for gestational age and sex). We used generalized estimating equations to examine the odds of LGA in pregnant individuals with gestational glucose intolerance compared with those with normal glucose tolerance, after adjustment for age, body mass index, parity, health insurance, race and ethnicity, and marital status. In addition, we investigated differences in birth weight-related adverse pregnancy outcomes. RESULTS Large for gestational age was present in 7.8% of 39,685 pregnant individuals with normal glucose tolerance, 9.5% of 4,155 pregnant individuals with gestational glucose intolerance and normal OGTT, 14.5% of 1,438 pregnant individuals with gestational glucose intolerance and one abnormal OGTT value, and 16.0% of 1,711 pregnant individuals with GDM. The adjusted odds of LGA were higher in pregnant individuals with gestational glucose intolerance than in those with normal glucose tolerance overall (adjusted odds ratio [aOR] 1.35, 95% CI 1.23-1.49, P <.001). When compared separately with pregnant individuals with normal glucose tolerance, those with either gestational glucose intolerance subtype had higher adjusted LGA odds (gestational glucose intolerance with normal OGTT aOR 1.21, 95% CI 1.08-1.35, P <.001; gestational glucose intolerance with one abnormal OGTT value aOR 1.77, 95% CI 1.52-2.08, P <.001). The odds of birth weight-related adverse outcomes (including cesarean delivery, severe perineal lacerations, and shoulder dystocia or clavicular fracture) were higher in pregnant individuals with gestational glucose intolerance with one abnormal OGTT value than in those with normal glucose tolerance. CONCLUSION Gestational glucose intolerance in pregnancy is associated with birth weight-related adverse pregnancy outcomes. Glucose lowering should be investigated as a strategy for lowering the risk of these outcomes in this group.
Collapse
Affiliation(s)
- Jacqueline Maya
- Diabetes Unit and Department of Medicine, Massachusetts General Hospital, Boston, MA, United States
- Department of Pediatrics, Massachusetts General Hospital, Boston, MA, United States
- Harvard Medical School, Boston, MA, United States
| | - Daryl J. Selen
- Department of Medicine, Division of Endocrinology, Warren Alpert Medical School of Brown University, Providence, RI, United States
| | - Tanayott Thaweethai
- Harvard Medical School, Boston, MA, United States
- Biostatistics Center, Massachusetts General Hospital, Boston, MA, United States
| | - Sarah Hsu
- Diabetes Unit and Department of Medicine, Massachusetts General Hospital, Boston, MA, United States
- Broad Institute of MIT and Harvard, Boston, MA, United States
| | - Devika Godbole
- Biostatistics Center, Massachusetts General Hospital, Boston, MA, United States
- Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, United States
| | | | - Kaitlyn James
- Harvard Medical School, Boston, MA, United States
- Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, United States
| | - Sarbattama Sen
- Harvard Medical School, Boston, MA, United States
- Department of Pediatric Newborn Medicine, Brigham and Women’s Hospital, Boston, MA, United States
| | - Anjali Kaimal
- Department of Obstetrics and Gynecology, Morsani College of Medicine, University of South Florida, Tampa, FL, United States
| | - Marie-France Hivert
- Diabetes Unit and Department of Medicine, Massachusetts General Hospital, Boston, MA, United States
- Division of Chronic Disease Research Across the Lifecourse (CoRAL), Department of Population Medicine, Harvard Medical School, Harvard Pilgrim Health Care Institute, Boston, MA, United States
| | - Camille E. Powe
- Diabetes Unit and Department of Medicine, Massachusetts General Hospital, Boston, MA, United States
- Harvard Medical School, Boston, MA, United States
- Broad Institute of MIT and Harvard, Boston, MA, United States
- Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, United States
| |
Collapse
|
8
|
Arroyo AC, Robinson LB, James K, Li S, Faridi MK, Hsu S, Dumas O, Liu AY, Druzin M, Powe CE, Camargo CA. Maternal Hypertensive Disorders of Pregnancy and the Risk of Childhood Asthma. Ann Am Thorac Soc 2023; 20:1367-1370. [PMID: 37233740 PMCID: PMC10502887 DOI: 10.1513/annalsats.202212-994rl] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2022] [Accepted: 05/23/2023] [Indexed: 05/27/2023] Open
Affiliation(s)
| | | | - Kaitlyn James
- Harvard Medical SchoolBoston, Massachusetts and
- Massachusetts General HospitalBoston, Massachusetts and
| | - Sijia Li
- Massachusetts General HospitalBoston, Massachusetts and
| | | | - Sarah Hsu
- Massachusetts General HospitalBoston, Massachusetts and
- Broad InstituteCambridge, Massachusetts
| | | | - Anne Y. Liu
- Stanford University School of MedicineStanford, California
| | - Maurice Druzin
- Stanford University School of MedicineStanford, California
| | - Camille E. Powe
- Harvard Medical SchoolBoston, Massachusetts and
- Massachusetts General HospitalBoston, Massachusetts and
| | - Carlos A. Camargo
- Harvard Medical SchoolBoston, Massachusetts and
- Massachusetts General HospitalBoston, Massachusetts and
| |
Collapse
|
9
|
Szymanski M, Mirza K, De Jonge N, Schmidt T, Brahmbhatt D, Billia F, Hsu S, MacGowan G, Jakovljevic D, Agostoni P, Trombara F, Jorde U, Rochlani Y, Vandersmissen K, Reiss N, Russell S, Meyns B, Gustafsson F. Prognostic Value of Repeated Peak Oxygen Uptake Measurements in LVAD Patients - Follow Up on PRO-VAD Study. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1644] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
10
|
Mehta A, Goldberg J, Bagchi P, Marboe C, Shah K, Najjar S, Hsu S, Rodrigo M, Jang M, Cochrane A, Tchoukina I, Kong H, Lohmar B, Mcnair E, Valantine H, Agbor-Enoh S, Berry G, Shah P. Cell-Free DNA Enhances Pathologist Interrater Reliability at the Assessment of Acute Rejection on Endomyocardial Biopsy, on Behalf of the GRAfT Investigators. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
11
|
Grewal J, Bortner B, Gregoski M, Cook D, Britt A, Hajj J, Rofael M, Sheidu M, Montovano M, Mehta M, Hajduczok A, Rajapreyar I, Brailovski Y, Genuardi M, Kanwar M, Atluri P, Lander M, Shah P, Hsu S, Kilic A, Houston B, Tedford R. Validation of the Heartmate 3 Risk Score in a Real World Patient Cohort. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
12
|
Goldberg J, deFilippi C, Lockhart C, McNair E, Sinha S, Kong H, Najjar S, Lohmar B, Tchoukina I, Shah K, Feller E, Hsu S, Rodrigo M, Jang M, Marboe C, Berry G, Valantine H, Agbor-Enoh S, Shah P. Dysregulated Circulating Proteins in Cellular and Antibody-Mediated Rejection, on Behalf of the Graft Investigators. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
13
|
Szymanski M, Mirza K, De Jonge N, Schmidt T, Brahmbhatt D, Billia F, Hsu S, MacGowan G, Jakovljevic D, Agostoni P, Trombara F, Jorde U, Rochlani Y, Vandersmissen K, Reiss N, Russell S, Meyns B, Gustafsson F. Improvement in Peak Oxygen Uptake During First Year of Mechanical Circulatory Support in End-Stage Heart Failure Patients - Follow Up on PRO-VAD Study. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
14
|
Maya J, James K, Hsu S, Thaweethai T, Hivert MF, Powe CE. Abstract P244: Gestational Glucose Intolerance is Associated With Hypertensive Disorders of Pregnancy in a Large Hospital-Based Multiethnic Cohort. Circulation 2023. [DOI: 10.1161/circ.147.suppl_1.p244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/16/2023]
Abstract
Introduction:
Hypertensive disorders of pregnancy (HDP) are associated with higher future cardiovascular risk. Treatment of gestational diabetes (GDM) has been shown to reduce the risk of HDP. It is unknown if women with gestational glucose intolerance (GGI), defined as abnormal GDM screening but without a GDM diagnosis, are at higher risk of HDP. Currently, GGI is not treated.
Hypothesis:
We tested the hypothesis that GGI pregnancies have increased odds of HDP.
Methods:
This is a retrospective cohort study of 41,706 singleton pregnancies delivered at an academic center. Based on the results of GDM screening and diagnostic tests, pregnancies were categorized as normal glucose tolerance (NGT, glucose loading test < 140 mg/dl), GGI (glucose loading test ≥140 mg/dl with 0 or 1 abnormal value on oral glucose tolerance testing [OGTT] thus without GDM), or GDM (≥ 2 abnormal values on OGTT). GGI was further classified into groups with zero (GGI-0) or 1 (GGI-1) abnormal OGTT values. We used laboratory, blood pressure, and delivery reports to capture HDP and exclude chronic hypertension. Generalized estimating equations for logistic regression were used to measure the risk of HDP after adjustment for age, 1st trimester BMI, parity, insurance, race/ethnicity, and marital status. A similar approach was used to test for associations between GGI and pre-eclampsia (PE).
Results:
A total of 84.5% of pregnancies were classified as NGT, 8.9% as GGI-0, 3.0% as GGI-1 and 3.6% as GDM. The unadjusted frequencies of HDP and PE were higher in GGI-1 (140 [11.2%] and 64 [5.1%] of 1,251) and GDM (165 [11.1%] and 94 [6.3%] of 1,485) compared to NGT (2,275 [6.5%] and 1,100 [3.1%] of 35,238) and GGI-0 (283 [7.6%] and 136 [3.6%] of 3,732). We observed greater odds of HDP in all 3 groups compared to NGT in adjusted models, and similar trends for PE (Figure 1).
Conclusions:
The risks of HDP and PE in GGI-1 are greater than for NGT pregnancies and similar to the risks in GDM. Our results suggest that women with GGI-1 should be considered for intervention, similar to GDM.
Collapse
Affiliation(s)
| | | | - Sarah Hsu
- Massachusetts General Hosp, Boston, MA
| | | | | | | |
Collapse
|
15
|
Hsu S, Selen DJ, James K, Li S, Camargo CA, Kaimal A, Powe CE. Assessment of the Validity of Administrative Data for Gestational Diabetes Ascertainment. Am J Obstet Gynecol MFM 2023; 5:100814. [PMID: 36396038 PMCID: PMC10071626 DOI: 10.1016/j.ajogmf.2022.100814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Accepted: 11/09/2022] [Indexed: 11/16/2022]
Abstract
BACKGROUND Administrative data, including International Classification of Diseases codes and birth certificate records, are often used for retrospective gestational diabetes research investigations to describe associations of gestational diabetes with perinatal complications and long-term outcomes, and to determine gestational diabetes prevalence. Research investigating the validity of using International Classification of Diseases codes and birth certificates for gestational diabetes ascertainment shows varying degrees of reliability. OBJECTIVE This study aimed to evaluate the accuracy of both International Classification of Diseases codes and birth certificate diagnosis for gestational diabetes ascertainment in a large hospital-based cohort of pregnant individuals, using laboratory criteria for gestational diabetes mellitus as the reference. STUDY DESIGN We studied individuals who received prenatal care at an academic hospital and affiliated community health centers between 1998 and 2016. In the setting of universal 2-step screening for gestational diabetes, pregnant individuals were classified as having gestational diabetes if ≥2 oral glucose tolerance test values met or exceeded National Diabetes Data Group thresholds. We calculated the sensitivity, specificity, positive predictive value, and negative predictive value for International Classification of Diseases code and birth certificate ascertainment of gestational diabetes, and their exact binomial 95% confidence intervals. RESULTS In a cohort of 51,059 pregnancies with complete glucose screening, 1303 (2.6%) met National Diabetes Data Group laboratory criteria for gestational diabetes. Gestational diabetes International Classification of Diseases codes had moderate sensitivity of 70.5% (95% confidence interval, 67.9-72.9), high specificity of 99.3% (95% confidence interval, 99.3-99.4), a positive predictive value of 73.3% (95% confidence interval, 70.8-75.8), and a negative predictive value of 99.2% (95% confidence interval, 99.1-99.3). In the 46,512 pregnancies linked to birth certificate data, birth certificate diagnosis had moderate sensitivity (66.3% [95% confidence interval, 63.6-69.0]), high specificity (98.9% [95% confidence interval, 98.8-99.0]), moderate positive predictive value (62.1% [95% confidence interval, 59.8-64.4]), and high negative predictive value (99.1% [95% confidence interval, 99.0-99.2]). CONCLUSION Ascertainment of gestational diabetes using administrative data, including International Classification of Diseases codes or birth certificates, has moderate sensitivity, moderate positive predictive value, high specificity, and high negative predictive value. Our findings provide context for interpreting the validity of studies that depend on administrative data for ascertainment of gestational diabetes and comparing them with prospective studies that use laboratory-based gestational diabetes criteria.
Collapse
Affiliation(s)
- Sarah Hsu
- Diabetes Unit, Massachusetts General Hospital, Boston, MA (Ms Hsu and Drs Selen and Powe); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (Ms Hsu and Dr Powe)
| | - Daryl J Selen
- Diabetes Unit, Massachusetts General Hospital, Boston, MA (Ms Hsu and Drs Selen and Powe); Harvard Medical School, Boston, MA (Drs Selen, James, Camargo, Kaimal, and Powe)
| | - Kaitlyn James
- Harvard Medical School, Boston, MA (Drs Selen, James, Camargo, Kaimal, and Powe); Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA (Drs James, Kaimal, and Powe)
| | - Sijia Li
- Department of Medicine, Division of Endocrinology, Warren Alpert Medical School of Brown University, Providence, RI (Dr. Selen), Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA (Ms Li and Dr Camargo)
| | - Carlos A Camargo
- Harvard Medical School, Boston, MA (Drs Selen, James, Camargo, Kaimal, and Powe); Department of Medicine, Division of Endocrinology, Warren Alpert Medical School of Brown University, Providence, RI (Dr. Selen), Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA (Ms Li and Dr Camargo)
| | - Anjali Kaimal
- Harvard Medical School, Boston, MA (Drs Selen, James, Camargo, Kaimal, and Powe); Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA (Drs James, Kaimal, and Powe)
| | - Camille E Powe
- Diabetes Unit, Massachusetts General Hospital, Boston, MA (Ms Hsu and Drs Selen and Powe); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (Ms Hsu and Dr Powe); Harvard Medical School, Boston, MA (Drs Selen, James, Camargo, Kaimal, and Powe); Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA (Drs James, Kaimal, and Powe).
| |
Collapse
|
16
|
Selen DJ, Thaweethai T, Schulte CC, Hsu S, He W, James K, Kaimal A, Meigs JB, Powe CE. Gestational Glucose Intolerance and Risk of Future Diabetes. Diabetes Care 2023; 46:83-91. [PMID: 36473077 PMCID: PMC9797650 DOI: 10.2337/dc22-1390] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Accepted: 10/10/2022] [Indexed: 12/12/2022]
Abstract
OBJECTIVE Pregnant individuals are universally screened for gestational diabetes mellitus (GDM). Gestational glucose intolerance (GGI) (an abnormal initial GDM screening test without a GDM diagnosis) is not a recognized diabetes risk factor. We tested for an association between GGI and diabetes after pregnancy. RESEARCH DESIGN AND METHODS We conducted a retrospective cohort study of individuals followed for prenatal and primary care. We defined GGI as an abnormal screening glucose-loading test result at ≥24 weeks' gestation with an oral glucose tolerance test (OGTT) that did not meet GDM criteria. The primary outcome was incident diabetes. We used Cox proportional hazards models with time-varying exposures and covariates to compare incident diabetes risk in individuals with GGI and normal glucose tolerance. RESULTS Among 16,836 individuals, there were 20,359 pregnancies with normal glucose tolerance, 2,943 with GGI, and 909 with GDM. Over a median of 8.4 years of follow-up, 428 individuals developed diabetes. Individuals with GGI had increased diabetes risk compared to those with normal glucose tolerance in pregnancy (adjusted hazard ratio [aHR] 2.01 [95% CI 1.54-2.62], P < 0.001). Diabetes risk increased with the number of abnormal OGTT values (zero, aHR 1.54 [1.09-2.16], P = 0.01; one, aHR 2.97 [2.07-4.27], P < 0.001; GDM, aHR 8.26 [6.49-10.51], P < 0.001 for each compared with normal glucose tolerance). The fraction of cases of diabetes 10 years after delivery attributable to GGI and GDM was 8.5% and 28.1%, respectively. CONCLUSIONS GGI confers an increased risk of future diabetes. Routinely available clinical data identify an unrecognized group who may benefit from enhanced diabetes screening and prevention.
Collapse
Affiliation(s)
- Daryl J. Selen
- Diabetes Unit, Massachusetts General Hospital, Boston, MA
- Department of Medicine, Massachusetts General Hospital, Boston, MA
- Harvard Medical School, Boston, MA
- Division of Endocrinology, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, RI
| | - Tanayott Thaweethai
- Department of Medicine, Massachusetts General Hospital, Boston, MA
- Harvard Medical School, Boston, MA
- Biostatistics Center, Division of Clinical Research, Massachusetts General Hospital, Boston, MA
| | - Carolin C.M. Schulte
- Biostatistics Center, Division of Clinical Research, Massachusetts General Hospital, Boston, MA
- Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA
| | - Sarah Hsu
- Diabetes Unit, Massachusetts General Hospital, Boston, MA
- Department of Medicine, Massachusetts General Hospital, Boston, MA
- Broad Institute of MIT and Harvard, Boston, MA
| | - Wei He
- Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA
| | - Kaitlyn James
- Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA
| | - Anjali Kaimal
- Harvard Medical School, Boston, MA
- Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA
| | - James B. Meigs
- Department of Medicine, Massachusetts General Hospital, Boston, MA
- Harvard Medical School, Boston, MA
- Broad Institute of MIT and Harvard, Boston, MA
- Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA
| | - Camille E. Powe
- Diabetes Unit, Massachusetts General Hospital, Boston, MA
- Department of Medicine, Massachusetts General Hospital, Boston, MA
- Harvard Medical School, Boston, MA
- Broad Institute of MIT and Harvard, Boston, MA
- Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA
| |
Collapse
|
17
|
Slutzman JE, Bockius H, Gordon IO, Greene HC, Hsu S, Huang Y, Lam MH, Roberts T, Thiel CL. Waste audits in healthcare: A systematic review and description of best practices. Waste Manag Res 2023; 41:3-17. [PMID: 35652693 PMCID: PMC9925917 DOI: 10.1177/0734242x221101531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Accepted: 04/30/2022] [Indexed: 06/15/2023]
Abstract
Healthcare generates large amounts of waste, harming both environmental and human health. Waste audits are the standard method for measuring and characterizing waste. This is a systematic review of healthcare waste audits, describing their methods and informing more standardized auditing and reporting. Using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we searched MEDLINE, Embase, Inspec, Scopus and Web of Science Core Collection databases for published studies involving direct measurement of waste in medical facilities. We screened 2398 studies, identifying 156 studies for inclusion from 37 countries. Most were conducted to improve local waste sorting policies or practices, with fewer to inform policy development, increase waste diversion or reduce costs. Measurement was quantified mostly by weighing waste, with many also counting items or using interviews or surveys to compile data. Studies spanned single procedures, departments and hospitals, and multiple hospitals or health systems. Waste categories varied, with most including municipal solid waste or biohazardous waste, and others including sharps, recycling and other wastes. There were significant differences in methods and results between high- and low-income countries. The number of healthcare waste audits published has been increasing, with variable quality and general methodologic inconsistency. A greater emphasis on consistent performance and reporting standards would improve the quality, comparability and usefulness of healthcare waste audits.
Collapse
Affiliation(s)
- Jonathan E Slutzman
- Center for the Environment and
Health, Massachusetts General Hospital, Boston, MA, USA
- Department of Emergency Medicine,
Massachusetts General Hospital, Harvard Medical School, Boston, MA,
USA
| | - Hannah Bockius
- Department of Biomedical
Engineering, University of Delaware, Newark, DE, USA
| | - Ilyssa O Gordon
- Robert J. Tomsich Pathology &
Laboratory Medicine Institute, Department of Pathology, Cleveland Clinic,
Cleveland, OH, USA
| | - Hannah C Greene
- Department of Biology, New York
University Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - Sarah Hsu
- Warren Alpert Medical School,
Brown University, Providence, RI, USA
| | | | - Michelle H Lam
- Department of Chemical and
Biomolecular Engineering, NYU Tandon School of Engineering, Brooklyn, NY,
USA
| | - Timothy Roberts
- Health Sciences Library, NYU
Langone Health, Grossman School of Medicine, New York University, New York,
NY, USA
| | - Cassandra L Thiel
- Grossman School of Medicine,
Wagner Graduate School of Public Service, Tandon School of Engineering, New
York University, New York, NY, USA
| |
Collapse
|
18
|
Sarma AA, Hsu S, Januzzi JL, Goldfarb IT, Thadhani R, Wood MJ, Powe CE, Scott NS. First Trimester Cardiac Biomarkers among Women with Peripartum Cardiomyopathy: Are There Early Clues to This Late-Pregnancy Phenomenon? Am J Perinatol 2023; 40:137-140. [PMID: 35523213 DOI: 10.1055/s-0042-1748159] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
OBJECTIVE Whether biomarkers may enable early identification of women who develop peripartum cardiomyopathy (PPCM) prior to disease onset remains a question of interest. STUDY DESIGN A retrospective nested case-control study was conducted to determine whether first trimester N-terminal pro-B type natriuretic peptide (NT-proBNP) or high sensitivity cardiac troponin I (hs-cTnI) differed among women who developed PPCM versus unaffected pregnancies. Cases were matched to unaffected women by age, race, parity, and gestational age of sample (control A) and then further by blood pressure and pregnancy weight gain (control B). RESULTS First trimester NT-proBNP concentrations were numerically higher among women who subsequently developed PPCM (116 pg/mL [83-177]) as compared with women in control A (56.1 pg/mL [38.7-118.7], p = 0.3) or control B (37.6 [23.3 - 53.8], p <0.05). A higher proportion of women who subsequently developed PPCM (50%) had detectable levels of hs-cTnI as compared with control A (0%, p = 0.03) or control B (18.8%, p = 0.52). Among both cases and controls, hs-cTnI values were low and often below the limit of detection. CONCLUSION There were differences in first trimester NT-proBNP and hs-cTnI concentrations between women who subsequently developed PPCM and those who did not, raising the possibility the early pregnancy subclinical myocardial dysfunction may be associated with this late-pregnancy disease. KEY POINTS · First trimester NT-proBNP is numerically higher among women who subsequently develop PPCM.. · First trimester hs-cTnI was nominally higher among women who developed PPCM versus those who did not.. · A significant proportion of normal pregnant women have undetectable hs-cTnI..
Collapse
Affiliation(s)
- Amy A Sarma
- Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.,Harvard Medical School, Boston, Massachusetts
| | - Sarah Hsu
- Division of Endocrinology, Diabetes Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
| | - James L Januzzi
- Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.,Harvard Medical School, Boston, Massachusetts
| | - Ilona T Goldfarb
- Harvard Medical School, Boston, Massachusetts.,Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, Massachusetts
| | - Ravi Thadhani
- Harvard Medical School, Boston, Massachusetts.,Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
| | - Malissa J Wood
- Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.,Harvard Medical School, Boston, Massachusetts
| | - Camille E Powe
- Harvard Medical School, Boston, Massachusetts.,Division of Endocrinology, Diabetes Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
| | - Nandita S Scott
- Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.,Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
19
|
Dumas O, Arroyo AC, Faridi MK, James K, Hsu S, Powe C, Camargo CA. Cohort Study of Maternal Gestational Weight Gain, Gestational Diabetes, and Childhood Asthma. Nutrients 2022; 14:nu14235188. [PMID: 36501218 PMCID: PMC9741125 DOI: 10.3390/nu14235188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Revised: 11/25/2022] [Accepted: 12/02/2022] [Indexed: 12/12/2022] Open
Abstract
Data on the association of maternal gestational weight gain (GWG) and gestational diabetes mellitus (GDM) with childhood asthma are limited and inconsistent. We aimed to investigate these associations in a U.S. pre-birth cohort. Analyses included 16,351 mother-child pairs enrolled in the Massachusetts General Hospital Maternal-Child Cohort (1998-2010). Data were obtained by linking electronic health records for prenatal visits/delivery to determine BMI, GWG, and GDM (National Diabetes Data Group criteria) and to determine asthma incidence and allergies (atopic dermatitis or allergic rhinitis) for children. The associations of prenatal exposures with asthma were evaluated using logistic regression adjusted for maternal characteristics. A total of 2306 children (14%) developed asthma by age 5 years. Overall, no association was found between GWG and asthma. GDM was positively associated with offspring asthma (OR 1.46, 95% CI 1.14-1.88). Associations between GDM and asthma were observed only among mothers with early pregnancy BMI between 20 and 24.9 kg/m2 (OR 2.31, CI 1.46-3.65, p-interaction 0.02). We report novel findings on the impact of prenatal exposures on asthma, including increased risk among mothers with GDM, particularly those with a normal BMI. These findings support the strengthening of interventions targeted toward a healthier pregnancy, which may also be helpful for childhood asthma prevention.
Collapse
Affiliation(s)
- Orianne Dumas
- Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Équipe d’Épidémiologie Respiratoire Intégrative, CESP, 94807 Villejuif, France
- Correspondence:
| | - Anna Chen Arroyo
- Division of Pulmonary, Allergy & Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Mohammad Kamal Faridi
- Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
| | - Kaitlyn James
- Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Sarah Hsu
- Diabetes Unit, Massachusetts General Hospital, Boston, MA 02114, USA
- Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Camille Powe
- Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA 02114, USA
- Diabetes Unit, Massachusetts General Hospital, Boston, MA 02114, USA
- Harvard Medical School, Boston, MA 02115, USA
- Broad Institute, Cambridge, MA 02142, USA
| | - Carlos A. Camargo
- Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
| |
Collapse
|
20
|
Hsu S, Stevens D, Sajjad F, Salapatek A. ONSET OF ACTION OF AZELASTINE HCL NASAL SPRAY 0.15% EVALUATED IN AN ENVIRONMENTAL EXPOSURE CHAMBER. Ann Allergy Asthma Immunol 2022. [DOI: 10.1016/j.anai.2022.08.704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
21
|
Duckworth M, Hsu S, Boehler-Tatman M. Preparing the Next Generation of Health Professionals to Tackle Climate Change. Acad Med 2022; 97:1105. [PMID: 34380924 DOI: 10.1097/acm.0000000000004341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Affiliation(s)
- Megan Duckworth
- Medical student, Warren Alpert Medical School of Brown University, Providence, Rhode Island; ; ORCID: https://orcid.org/0000-0002-7661-2463
| | - Sarah Hsu
- Medical student, Warren Alpert Medical School of Brown University, Providence, Rhode Island
| | - Mattie Boehler-Tatman
- Medical student, Warren Alpert Medical School of Brown University, Providence, Rhode Island
| |
Collapse
|
22
|
Bai E, Pallant B, Bliss H, Hsu S, Cineas S, Geary M. The LIC fellow: A novel medical student peer-mentorship role. Med Educ 2022; 56:552. [PMID: 35212021 DOI: 10.1111/medu.14751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
|
23
|
Bon A, Gerhard E, Mathew J, Kong H, Jang M, Henry L, Lee B, Hsu S, Shah K, Tchoukina I, Sterling S, Rodrigo M, Najjar S, Marboe C, Berry G, Valantine H, Shah P, Agbor-Enoh S. Cell-Free DNA to Distinguish High Risk Donor Specific Antibodies in Heart Transplantation. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.1209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
24
|
Scheel P, Tsou B, Kauffman M, Drakos S, Weller A, Sharma K, Kilic A, Hsu S. Right Ventricle Pressure-Volume Analysis During LVAD Explant Evaluation. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.1724] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
25
|
Shah P, Agbor-Enoh S, Bagchi P, deFilippi C, Mercado A, Diao G, Morales D, Shah K, Najjar S, Feller E, Hsu S, Rodrigo M, Lewsey S, Jang M, Marboe C, Berry G, Khush K, Valantine H. Circulating microRNA Biomarkers in Cellular and Antibody-Mediated Heart Transplant Rejection. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
26
|
Jani V, Aslam M, Salazar IC, Kass D, Hsu S. Unsupervised Machine Learning to Identify and Target Myofilament Mechanisms of Clinical RV Dysfunction in HFrEF. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
27
|
McCarthy AM, Manning AK, Hsu S, Moy B, Lehman CD, Armstrong K. Abstract P3-13-01: Association of polygenic risk score with 2 year risk of poor prognosis breast cancer. Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-p3-13-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Mammography reduces breast cancer mortality, however, there is controversy surrounding when and how often women should undergo mammography screening. Knowledge of short-term risk of developing breast cancer, particularly poor prognosis breast cancer, would help direct more intensive screening to those at highest risk. Polygenic risk scores (PRS) are emerging as a powerful tool to predict breast cancer risk, however, few studies have evaluated the associations of breast cancer PRS with short-term risk or with risk of poor prognosis breast cancers specifically. Methods: Using a mammography screening cohort at Massachusetts General Hospital, we identified women who had a negative mammogram (BI-RADS assessment 1 or 2) from 2006 to 2015. We linked the cohort to a research biobank to obtain genetic information. In addition, we recruited 205 patients who developed breast cancer within 2 years of a negative mammogram to provide a DNA sample. Women with a prior history of breast cancer, with breast implants, and who were not residents of Massachusetts were excluded. Samples were genotyped using the Illumina Multi-Ethnic GWAS/Exome SNP (MEGA) array. Genotypes were imputed using TOPMed (Version r2 2020). Patients whose saliva DNA samples had low concentration or that failed quality control procedures were excluded. Ancestry specific principal components were generated and used as a covariate. We generated the 313-SNP breast cancer PRS, the estrogen receptor positive (ER+) PRS and the estrogen receptor negative (ER-) PRS using established methods. (PMID: 30554720) Breast cancers were defined as poor prognosis if they were metastatic, had positive lymph nodes, were ER/PR+HER2- and > 2cm or ER/PR/HER2- or HER2+ and > 1cm. (PMID: 33169794) Logistic regression was used to estimate the odds ratios for standardized PRS measures, adjusted for age, breast density, race/ethnicity, year of screening, and ancestry principal components. Results: After exclusions, 308 breast cancers and 3329 non-cases were analyzed. Of the breast cancers, 86% were ER/PR+ (264/308) and 14% were ER/PR- (42/308), and 137 (44%) were poor prognosis. The majority of patients were non-Hispanic White (87%) and the mean age was 57 years and was similar for cancers and non-cancers. Cancer cases were more likely than non-cases to have higher breast density and a family history of breast cancer. First, we examined the overall breast cancer PRS, and found the PRS was significantly associated with breast cancer diagnosed within two years of a negative mammogram (OR=1.39, 95% CI 1.23-1.57, p < 0.001). The PRS was also significantly associated specifically with diagnosis of poor prognosis disease (OR=1.21, 95% CI 1.01-1.45, p=0.037). In addition, the ER+ PRS was significantly associated with ER/PR+ breast cancer (OR=1.41, 95% CI 1.24-1.61, p < 0.001), and the ER- PRS was significantly associated with ER- breast cancer (OR=1.48, 95% CI 1.08-2.02, p=0.015). Conclusion: Even after adjusting for breast density and other risk factors, breast cancer PRS was significantly associated with diagnosis of both breast cancer overall and poor prognosis breast cancer within two years of a negative mammogram. Furthermore, the subtype specific PRS were significantly associated with short-term risk of ER+ and ER- disease. These results suggest that PRS may be useful in guiding decisions about screening interval and supplemental screening, given the association of PRS with risk of poor prognosis disease in the short term.
Table 1.Logistic Regression of PRS and cancer diagnosis within 2 years of a negative mammogramOR95% CIp-valueAll Cancers (N=308), Overall PRS1.391.23-1.571.78x10-7Poor prognosis (N=147), Overall PRS1.211.01-1.450.037ER+ cancers (N=264), ER+ PRS1.421.24-1.621.87x10-7ER- cancers (N=42), ER- PRS1.521.11-2.090.008
Citation Format: Anne Marie McCarthy, Alisa K. Manning, Sarah Hsu, Beverly Moy, Constance D. Lehman, Katrina Armstrong. Association of polygenic risk score with 2 year risk of poor prognosis breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-13-01.
Collapse
Affiliation(s)
| | | | - Sarah Hsu
- Massachusetts General Hospital, Boston, MA
| | | | | | | |
Collapse
|
28
|
Arroyo A, Robinson L, James K, Li S, Hsu S, Liu A, Druzin M, Powe C, Camargo C. Maternal hypertensive disorders of pregnancy and the risk of childhood asthma. J Allergy Clin Immunol 2022. [DOI: 10.1016/j.jaci.2021.12.312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Aslam M, Minhas A, Ghorbani A, Shade J, Jani V, Hsu S, Sharma K, Cihakova D, Hays A, Gilotra N. Natriuretic Peptide Levels and Clinical Outcomes among Patients Hospitalized with COVID-19 Infection. J Heart Lung Transplant 2021. [PMCID: PMC7979424 DOI: 10.1016/j.healun.2021.01.606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Purpose There is increasing evidence of adverse cardiovascular morbidity associated with SARS-CoV-2 (COVID-19). Pro-B-type natriuretic peptide (proBNP) is a biomarker of myocardial stress associated with outcomes in various respiratory and cardiac diseases. We hypothesized that proBNP level would be associated with mortality and clinical outcomes in hospitalized COVID-19 patients. Methods We performed a retrospective analysis of hospitalized COVID-19 patients (n=1232) using adjusted logistic and linear regression to assess the association of admission proBNP (analyzed by both categorical cutoff >125 pg/mL and continuous log transformed proBNP) with clinical outcomes. Covariates included age, sex, race, body mass index (BMI), hypertension, coronary artery disease (CAD), diabetes, smoking history, and chronic kidney disease stage (Model 1), with Troponin I added in Model 2. We performed survival analysis by a multivariate Cox proportional hazard model, incorporating log transformed proBNP. We additionally treated BMI, a strong potential confounder of both proBNP levels and COVID-19 outcomes, as an ordinal variable ordered across tertiles. Results Patients were mean age 62.9±17.6, 53.8% male, and 35.9% Black. Preadmission comorbidities were hypertension (57.1%), diabetes (31.6%), CAD (9.0%) and heart failure (HF, 10.6%). In Model 1 and 2, higher proBNP level was significantly associated with death, new HF, length of stay, ICU duration and need for ventilation among hospitalized COVID-19 patients. This significance persisted after ordinal compression of BMI across tertiles. The adjusted hazard ratio of death for log[proBNP] was 1.56 (95% CI: 1.23-1.97; P<0.0001). Conclusion Using a relatively large and racially diverse hospitalized COVID-19 patient cohort, we find that proBNP is associated with adverse clinical outcomes, including mortality and new HF in COVID-19. Further prospective investigation is warranted on the utility of proBNP for clinical prognostication in COVID-19.
Collapse
|
30
|
McGoldrick M, Barbur I, Etchill E, Giuliano K, Hsu S, Sharma K, Kilic A, Choi C. Impact of Pre-Transplant ECMO Duration on Heart Transplant Survival. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.1946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
31
|
Hahn V, Ghorbani A, Hsu S, Lewsey S, Sharma K, Wittstein I, Freed K, Sweren R, Handler J, Wagner-Johnston N, Sperati C, Chrispin J, Wake L, Halushka M, Kilic A, Gilotra N. Myocarditis as a Manifestation of a T Cell Lymphoproliferative Disorder in a Patient Undergoing Left Ventricular Assistance Device Implantation. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.2102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
32
|
Yang Y, Agbor-Enoh S, Ilker T, Hsu S, Russell S, Feller E, Shah K, Rodrigo M, Najjar S, Kong H, Pirooznia M, Jang M, Marboe C, Berry G, Shah P, Valantine H. Cardiac Allograft Injury in Patients of African Ancestry: Trends of Donor-Derived Cell-Free DNA Based on Genetic Ancestry. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.725] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
33
|
Powe CE, Udler MS, Hsu S, Allard C, Kuang A, Manning AK, Perron P, Bouchard L, Lowe WL, Scholtens D, Florez JC, Hivert MF. Genetic Loci and Physiologic Pathways Involved in Gestational Diabetes Mellitus Implicated Through Clustering. Diabetes 2021; 70:268-281. [PMID: 33051273 PMCID: PMC7876560 DOI: 10.2337/db20-0772] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2020] [Accepted: 10/08/2020] [Indexed: 12/17/2022]
Abstract
Hundreds of common genetic variants acting through distinguishable physiologic pathways influence the risk of type 2 diabetes (T2D). It is unknown to what extent the physiology underlying gestational diabetes mellitus (GDM) is distinct from that underlying T2D. In this study of >5,000 pregnant women from three cohorts, we aimed to identify physiologically related groups of maternal variants associated with GDM using two complementary approaches that were based on Bayesian nonnegative matrix factorization (bNMF) clustering. First, we tested five bNMF clusters of maternal T2D-associated variants grouped on the basis of physiology outside of pregnancy for association with GDM. We found that cluster polygenic scores representing genetic determinants of reduced β-cell function and abnormal hepatic lipid metabolism were associated with GDM; these clusters were not associated with infant birth weight. Second, we derived bNMF clusters of maternal variants on the basis of pregnancy physiology and tested these clusters for association with GDM. We identified a cluster that was strongly associated with GDM as well as associated with higher infant birth weight. The effect size for this cluster's association with GDM appeared greater than that for T2D. Our findings imply that the genetic and physiologic pathways that lead to GDM differ, at least in part, from those that lead to T2D.
Collapse
Affiliation(s)
- Camille E Powe
- Diabetes Unit, Endocrine Division, Massachusetts General Hospital, Boston, MA
- Broad Institute, Cambridge, MA
- Harvard Medical School, Boston, MA
| | - Miriam S Udler
- Diabetes Unit, Endocrine Division, Massachusetts General Hospital, Boston, MA
- Broad Institute, Cambridge, MA
- Harvard Medical School, Boston, MA
| | - Sarah Hsu
- Diabetes Unit, Endocrine Division, Massachusetts General Hospital, Boston, MA
- Broad Institute, Cambridge, MA
| | - Catherine Allard
- Centre de Recherche du Centre Hospitalier, Université de Sherbrooke, Sherbrooke, Quebec, Canada
| | - Alan Kuang
- Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
| | - Alisa K Manning
- Broad Institute, Cambridge, MA
- Harvard Medical School, Boston, MA
- Clinical and Translational Epidemiology Unit, Mongan Institute, Massachusetts General Hospital, Boston, MA
| | - Patrice Perron
- Department of Medicine, Université de Sherbrooke, Quebec, Canada
| | - Luigi Bouchard
- Centre de Recherche du Centre Hospitalier, Université de Sherbrooke, Sherbrooke, Quebec, Canada
- Department of Biochemistry and Functional Genomics, Université de Sherbrooke, Sherbrooke, Quebec, Canada
- Department of Medical Biology, CIUSSS Saguenay-Lac-Saint-Jean-Hôpital Universitaire de Chicoutimi, Saguenay, Quebec, Canada
| | - William L Lowe
- Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
| | - Denise Scholtens
- Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
| | - Jose C Florez
- Diabetes Unit, Endocrine Division, Massachusetts General Hospital, Boston, MA
- Broad Institute, Cambridge, MA
- Harvard Medical School, Boston, MA
| | - Marie-France Hivert
- Diabetes Unit, Endocrine Division, Massachusetts General Hospital, Boston, MA
- Harvard Medical School, Boston, MA
- Department of Medicine, Université de Sherbrooke, Quebec, Canada
- Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA
| |
Collapse
|
34
|
Abstract
INTRODUCTION Healthcare contributes 10% of greenhouse gases in the United States and generates two milion tons of waste each year. Reducing healthcare waste can reduce the environmental impact of healthcare and lower hospitals' waste disposal costs. However, no literature to date has examined US emergency department (ED) waste management. The purpose of this study was to quantify and describe the amount of waste generated by an ED, identify deviations from waste policy, and explore areas for waste reduction. METHODS We conducted a 24-hour (weekday) ED waste audit in an urban, tertiary-care academic medical center. All waste generated in the ED during the study period was collected, manually sorted into separate categories based on its predominant material, and weighed. We tracked deviations from hospital waste policy using the hospital's Infection Control Manual, state regulations, and Health Insurance Portability and Accountability Act standards. Lastly, we calculated direct pollutant emissions from ED waste disposal activities using the M+WasteCare Calculator. RESULTS The ED generated 671.8 kilograms (kg) total waste during a 24-hour collection period. On a per-patient basis, the ED generated 1.99 kg of total waste per encounter. The majority was plastic (64.6%), with paper-derived products (18.4%) the next largest category. Only 14.9% of waste disposed of in red bags met the criteria for regulated medical waste. We identified several deviations from waste policy, including loose sharps not placed in sharps containers, as well as re-processable items and protected health information thrown in medical and solid waste. We also identified over 200 unused items. Pollutant emissions resulting per day from ED waste disposal include 3110 kg carbon dioxide equivalent and 576 grams of other criteria pollutants, heavy metals, and toxins. CONCLUSION The ED generates significant amounts of waste. Current ED waste disposal practices reveal several opportunities to reduce total waste generated, increase adherence to waste policy, and reduce environmental impact. While our results will likely be similar to other urban tertiary EDs that serve as Level I trauma centers, future studies are needed to compare results across EDs with different patient volumes or waste generation rates.
Collapse
Affiliation(s)
- Sarah Hsu
- Warren Alpert Medical School of Brown University, Providence, Rhode Island
| | - Cassandra L Thiel
- New York University Grossman School of Medicine, Department of Population Health, New York, New York
| | - Michael J Mello
- Warren Alpert Medical School of Brown University, Department of Emergency Medicine, Providence, Rhode Island
| | - Jonathan E Slutzman
- Massachusetts General Hospital and Harvard Medical School, Department of Emergency Medicine, Boston, Massachusetts
| |
Collapse
|
35
|
Wu S, Hsu S, Zhang Q, Greenlees L, Xiao M, Gupta A. Abstract 5717: LncRNA RP11-291B21.2 is associated with Durvalumab response in NSCLC and BLCA cancers. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-5717] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
Long noncoding RNAs (lncRNAs) are interacting with oncogenes, tumor suppressors and immune genes by regulating their expression and activity of relevant transcription factors, RNA-binding proteins, and microRNAs. Dysregulated lncRNAs in immune cells are associated with excessive or uncontrolled inflammation, and play vital roles in innate immune responses, carcinogenesis and tumor microenvironment (TME). Understanding potential associations of lncRNAs with bladder cancer (BLCA) and non-small cell lung cancer (NSCLC) patients treated by ICB agents, such as durvalumab, is emerging.
Methods
RNAseq data from CP1108 (NCT01693562) clinical trial samples (97 NSCLC samples and 66 BLCA samples treated by durvalumab monotherapy) were processed using a comprehensive annotated genome (GRCh38.p12, release 28). The normalized lncRNA expression was reported, significantly differentially expressed lncRNAs between RECIST responders and non-responders in both BLCA and NSCLC patients were then identified using R limma package. Single-cell RNAseq data analysis was done with R Seurat package. Correlation analysis between interested lncRNAs and known oncogenic or immune genes was carried out using Spearman's rho metric in both CP1108 and TCGA RNAseq datasets. Kaplan-Meier survival analysis (OS and PFS) was performed and log-rank p-value was reported.
Results
Eight lncRNAs (RP4-740C4.7, AL1333245.1, RP11-284F21.10, RP5-1139B12.4, RP11-291B21.2, CTD-3064M3.7, TRG-AS1, and RP11-291B21.2) were identified to be differentially expressed between durvalumab responders and non-responders in both CP1108 BLCA and NSCLC tumors. RP11-291B21.2 is the most interested lncRNAs since 6 of 7 its upstream proximity genes (up to 300kb) are killer cell lectin like receptors (KLRs): KLRC1, KLRC2, KLRC3, KLRC4, KLRK1, GABARAPL1, and KLRD1 and they are all significantly correlated with the expression of RP11-291B21.2. Co-expression analysis has shown that lncRNA RP11-291B21.2 is highly correlated with multiple key immune genes, including NK / T cells markers and IFNg induced genes, suggesting its important role in regulating tumor microenvironment. The analysis of scRNAseq data of NSCLC tumors suggests RP11-291B21.2 is dominantly expressed in CD8+ T cells, especially in exhaustive T cells. RP11-291B21.2 is also confirmed to be highly expressed (FC>1.8, p<0.03) in exhausted CD8+ T cells both 40h and day 6 after stimulation in the in vitro experiments. Survival analysis has revealed high expression of RP11-291B21.2 is associated with better survival for patients treated by durvalumab in NSCLC and BLCA (HR=~0.3), but not for patients treated with chemotherapy in TCGA datasets. In conclusion, high expression of RP11-291B21.2 predicts better survival to NSCLC and BLCA patients treated by durvalumab which may suggest that RP11-291B21.2 is a potential lncRNA biomarker to PD1/PDL1 blockage.
Citation Format: Song Wu, Sarah Hsu, Qu Zhang, Lydia Greenlees, Mike Xiao, Ashok Gupta. LncRNA RP11-291B21.2 is associated with Durvalumab response in NSCLC and BLCA cancers [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5717.
Collapse
Affiliation(s)
- Song Wu
- 1Astrazeneca, Gaithersburg, MD
| | | | | | | | | | | |
Collapse
|
36
|
Brusca S, Jang M, Shah P, Shah K, Hsu S, Feller E, E M, Najjar S, Fideli U, Kong H, Marishta A, Bhatti K, Yang Y, Tunc I, Solomon M, Berry G, Marboe C, Agbor-Enoh S, Valantine H. Early Donor-Derived Cell-Free DNA Predicts Peak Allograft Function in Heart Transplant. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.1261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
37
|
Freed K, Cuomo K, Hubbard A, Riley S, Menzel K, Sharma K, Florido R, Hsu S, Kilic A, Choi C, Aslam M, Umapathi P, Fioretti R, Klemans N, Gilotra N. Management of Heart Failure in Left Ventricular Assist Device (LVAD) Patients Utilizing an Outpatient Diuresis Clinic. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
38
|
Giuliano K, Canner J, Etchill E, Suarez-Pierre A, Velez A, Choi C, Higgins R, Sharma K, Hsu S, Kilic A. De Novo Malignancy after Heart Transplantation. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.1020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
39
|
Doshi A, Tushak Z, Kong H, Garcia V, Jang M, Shah P, Hsu S, Feller E, Rodrigo M, Najjar S, Fideli U, Marishta A, Bhatti K, Yang Y, Tunc I, Solomon M, Berry G, Marboe C, Agbor-Enoh S, Shah K, Valantine H. Increased Cell Free DNA Levels in African American Patients Early after Heart Transplantation. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
40
|
Philogene M, Massie A, Kong H, Shah P, Cochrane A, Ponor I, Levine D, Shah K, Hsu S, Feller E, Rodrigo M, Najjar S, Tunc I, Berry G, Marboe C, Jang M, Agbor-Enoh S, Valantine H. Association between Pretransplant Antibody against Angiotensin II Type 1 Receptor and Posttransplant Allograft Injury. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.1175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
41
|
Saeed D, Muslem R, Rasheed M, Caliskan K, Kalampokas N, Sipahi F, Lichtenberg A, Jawad K, Borger M, Huhn S, Cogswell R, John R, Schultz J, Shah H, Hsu S, Gilotra N, Tomashitis B, Hajj ME, Lozonschi L, Houston B, Tedford R. Less Invasive Surgical Implant Strategy is Associated with Significant Reduction in INTERMACS Defined Right Heart Failure Following LVAD Implantation. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.1005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
42
|
Khural J, Houston B, Leary P, Mathai S, Kolb T, Damico R, Paul H, Kass D, Hsu S, Tedford R. Right Atrial Pacing to Improve Acute Hemodynamics in Pulmonary Arterial Hypertension. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.1146] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
43
|
Alkhunaizi F, Ireland C, Damico R, Kolb T, Mathai S, Hassoun P, Kass D, Tedford R, Hsu S. Kussmaul's Sign Correlates with Pulmonary Vascular Pathology and Reduced Exercise Right Ventricular Output Reserve. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
44
|
Hsu S, Green L, Lebwohl M, Wu J, Blauvelt A, Jacobson A. Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials. Br J Dermatol 2019; 182:880-888. [DOI: 10.1111/bjd.18327] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/02/2019] [Indexed: 12/21/2022]
Affiliation(s)
- S. Hsu
- Temple University Lewis Katz School of Medicine Philadelphia PA U.S.A
| | - L.J. Green
- George Washington University School of Medicine & Health Sciences Washington DC U.S.A
| | - M.G. Lebwohl
- Icahn School of Medicine at Mount Sinai New York NY U.S.A
| | - J.J. Wu
- Dermatology Research and Education Foundation Irvine CA U.S.A
| | - A. Blauvelt
- Oregon Medical Research Center Portland OR U.S.A
| | | |
Collapse
|
45
|
Mollanazar N, Qiu C, Aldrich J, Tedaldi E, Valdes‐ Rodriguez R, Savage K, Hsu S. Use of dupilumab in patients who are HIV‐positive: report of four cases. Br J Dermatol 2019; 181:1311-1312. [DOI: 10.1111/bjd.18222] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- N.K. Mollanazar
- Department of Dermatology Lewis Katz School of Medicine at Temple University Philadelphia PA U.S.A
| | - C.C. Qiu
- Lewis Katz School of Medicine at Temple University Philadelphia PA U.S.A
| | - J.L. Aldrich
- Department of Medicine Lewis Katz School of Medicine at Temple University Philadelphia PA U.S.A
| | - E. Tedaldi
- Department of Medicine Lewis Katz School of Medicine at Temple University Philadelphia PA U.S.A
| | - R. Valdes‐ Rodriguez
- Department of Dermatology Lewis Katz School of Medicine at Temple University Philadelphia PA U.S.A
| | - K.T. Savage
- Drexel University College of Medicine Philadelphia PA U.S.A
| | - S. Hsu
- Department of Dermatology Lewis Katz School of Medicine at Temple University Philadelphia PA U.S.A
| |
Collapse
|
46
|
Levine JL, Xiang K, Su J, Hsu S, Kim RJ, Elayi S, Catanzaro JN. P1021Comparative efficacy of microfidelity technology vs standard ablation for atrioventricular nodal ablation. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Microfidelity Cateter Technology has proven efficacy in ablating atrial arrhythmias in multiple pilot studies. Closely spaced radial microelectrodes render a focused near-field electrogram. Case series suggest that this catheter design facilitates accurate ablations with fewer radiofrequency (RF) lesions. Atrioventricular junction (AVJ) ablation is regarded as a straightforward procedure, but case records show wide variance in procedure times and number of RF lesions required.
Methods
Twenty-four patients scheduled for AVJ ablation were randomized to treatment with either the Microfidelity technology or standard 8mm/8 French ablation catheter. Both groups located the AVJ by fluoroscopic landmarks and His electrograms, and the MiFi group used electroanatomical mapping to create the location of his electrograms. The primary endpoints were development of Junctional Rhythm (JR) or Complete Heart Block (CHB), and time from first RF lesion until rhythm change. Secondary endpoints included number of RF applications.
Results
Patients were randomized one-to-one to the MiFi arm or standard ablation arm. JR or CHB was achieved in all patients. Time from first RF lesion until JR/CHB was: (Median/IQR) 325 sec/250–1270 sec. vs 287 sec/101–406 sec. Number of RF applications was 5/3–15 applications vs 4.5/1–5 applications. Total procedure time in the lab was 134 min/73.5–172.5 min vs 58 min/52–146 min.
Microfidelity Technology vs Standard
Conclusion
Analysis suggests that the MiFi catheter is efficacious in ablating the AVJ, but requires greater RF duration and number of lesions, with wider case-by-case variability to achieve JR or CHB. Microfidelity technology and electroanatomical mapping did not result in faster time to completion than using fluoroscopic landmarks and His electrograms alone. Preoperative choice of sheath for catheter stability and contact may also play a role in a more efficient timely successful ablation of the AV node.
Acknowledgement/Funding
Boston Scientific
Collapse
Affiliation(s)
- J L Levine
- University of Florida, Jacksonville, United States of America
| | - K Xiang
- University of Florida, Jacksonville, United States of America
| | - J Su
- University of Florida, Jacksonville, United States of America
| | - S Hsu
- University of Florida, Jacksonville, United States of America
| | - R J Kim
- University of Florida, Jacksonville, United States of America
| | - S Elayi
- University of Florida, Jacksonville, United States of America
| | - J N Catanzaro
- University of Florida, Jacksonville, United States of America
| |
Collapse
|
47
|
Yalcin YC, Muslem R, Papageorgiou G, Tedford RJ, Constantinescu AA, Birim OC, Brugts JJ, Manintveld OC, Hsu S, Leebeek FWG, Bogers AJJC, Caliskan K. P1675Evolution of lactate dehydrogenase levels in patients with HeartMate II, HeartWare and HeartMate 3 left ventricular assist devices during first-year follow-up. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Lactate dehydrogenase (LDH) is considered as a biomarker of thrombotic events in patients receiving a left ventricular assist device (LVAD).
Purpose
This study aimed to investigate the evolution of LDH levels over time between patients supported with a HeartMate II (HMII), HeartMate 3 (HM3) or HeartWare (HVAD) LVAD during their first-year post implantation.
Methods
We analyzed in this multi-center retrospective study, all patients with HMII, HM3 and HVAD LVAD implanted between December 2006 and April 2017. Patients were classified into three groups based on their device type. Loess splines over time were used to depict the repeated measurements of LDH.
Results
In total, 134 patients received an LVAD (77% male, mean age 55 [46–61]), of whom 64 (48%) were HMII, 22 (16%) HM3 and 48 (36%) were HVAD. Loess splines over time indicate that there could be a considerable difference between evolution of LDH (Figure). During the first-year follow-up, 3 (5%) patients had a confirmed and 10 (16%) patients had a suspected pump thrombosis in the HMII group. For the HVAD, there were 6 (13%) patients with confirmed thrombosis and 1 (2%) case of suspected thrombosis, whereas none of the patients in the HM3 group experienced a suspected or confirmed pump thrombosis (p=0.01). The 1-year overall survival rate for HM II, HM3 and HVAD was 84%, 86% and 72% respectively (p=0.311). The overall stroke-free rate at one year was: 89%, 77% and 91% for HMII, HVAD and HM3 respectively (p=0.15).
Means of observed LDH values over time
Conclusion
During the first-year post LVAD implantation, there appear to be different evolutions of LDH levels over time in HMII device patients compared to HVAD or HM3 device patients. Given differences in baseline hemolysis levels between devices, currently used LDH thresholds for detection of impending pump thrombosis may be less sensitive and thus thresholds may be device specific.
Collapse
Affiliation(s)
- Y C Yalcin
- Erasmus Medical Center, Cardiothoracic Surgery + Cardiology, Rotterdam, Netherlands (The)
| | - R Muslem
- Erasmus Medical Center, Cardiothoracic Surgery + Cardiology, Rotterdam, Netherlands (The)
| | - G Papageorgiou
- Erasmus Medical Center, Biostatistics, Rotterdam, Netherlands (The)
| | - R J Tedford
- Medical University of South Carolina, Medicine, Charleston, United States of America
| | | | - O C Birim
- Erasmus Medical Center, Cardiothoracic Surgery, Rotterdam, Netherlands (The)
| | - J J Brugts
- Erasmus Medical Center, Cardiology, Rotterdam, Netherlands (The)
| | - O C Manintveld
- Erasmus Medical Center, Cardiology, Rotterdam, Netherlands (The)
| | - S Hsu
- Johns Hopkins University of Baltimore, Medicine, Baltimore, United States of America
| | - F W G Leebeek
- Erasmus Medical Center, Hematology, Rotterdam, Netherlands (The)
| | - A J J C Bogers
- Erasmus Medical Center, Cardiothoracic Surgery, Rotterdam, Netherlands (The)
| | - K Caliskan
- Erasmus Medical Center, Cardiology, Rotterdam, Netherlands (The)
| |
Collapse
|
48
|
Maisel A, Waldman A, Furlan K, Weil A, Sacotte K, Lazaroff JM, Lin K, Aranzazu D, Avram MM, Bell A, Cartee TV, Cazzaniga A, Chapas A, Crispin MK, Croix JA, DiGiorgio CM, Dover JS, Goldberg DJ, Goldman MP, Green JB, Griffin CL, Haimovic AD, Hausauer AK, Hernandez SL, Hsu S, Ibrahim O, Jones DH, Kaufman J, Kilmer SL, Lee NY, McDaniel DH, Schlessinger J, Tanzi E, Weiss ET, Weiss RA, Wu D, Poon E, Alam M. Self-reported Patient Motivations for Seeking Cosmetic Procedures. JAMA Dermatol 2019; 154:1167-1174. [PMID: 30140900 DOI: 10.1001/jamadermatol.2018.2357] [Citation(s) in RCA: 68] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Importance Despite the growing popularity of cosmetic procedures, the sociocultural and quality-of-life factors that motivate patients to undergo such procedures are not well understood. Objective To estimate the relative importance of factors that motivate patients to seek minimally invasive cosmetic procedures. Design, Setting, and Participants This prospective, multicenter observational study was performed at 2 academic and 11 private dermatology practice sites that represented all US geographic regions. Adult patients presenting for cosmetic consultation or treatment from December 4, 2016, through August 9, 2017, were eligible for participation. Exposures Participants completed a survey instrument based on a recently developed subjective framework of motivations and a demographic questionnaire. Main Outcomes and Measures Primary outcomes were the self-reported most common motivations in each quality-of-life category. Secondary outcomes were other frequently reported motivations and those associated with specific procedures. Results Of 529 eligible patients, 511 agreed to participate, were enrolled, and completed the survey. Typical respondents were female (440 [86.1%]), 45 years or older (286 [56.0%]), white (386 [75.5%]), and college educated (469 [91.8%]) and had previously received at least 2 cosmetic procedures (270 [52.8%]). Apart from motivations pertaining to aesthetic appearance, including the desire for beautiful skin and a youthful, attractive appearance, motives related to physical health, such as preventing worsening of condition or symptoms (253 of 475 [53.3%]), and psychosocial well-being, such as the desire to feel happier and more confident or improve total quality of life (314 of 467 [67.2%]), treat oneself or celebrate (284 of 463 [61.3%]), and look good professionally (261 of 476 [54.8%]) were commonly reported. Motivations related to cost and convenience were rated as less important (68 of 483 [14.1%]). Most motivations were internally generated, designed to please the patients and not others, with patients making the decision to undergo cosmetic procedures themselves and spouses seldom being influential. Patients younger than 45 years were more likely to undertake procedures to prevent aging (54 of 212 [25.5%] vs 42 of 286 [14.7%] among patients ≥45 years; P < .001). Patients seeking certain procedures, such as body contouring (19 of 22 [86.4%]), acne scar treatment (36 of 42 [85.7%]), and tattoo removal (8 of 11 [72.7%]), were more likely to report psychological and emotional motivations. Conclusions and Relevance This initial prospective, multicenter study comprehensively assessed why patients seek minimally invasive cosmetic procedures. Common reasons included emotional, psychological, and practical motivations in addition to the desire to enhance physical appearance. Differences relative to patient age and procedures sought may need further exploration.
Collapse
Affiliation(s)
- Amanda Maisel
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Abigail Waldman
- Department of Dermatology, Harvard Medical School, Boston, Massachusetts.,Department of Dermatology, Veterans Affairs Boston Healthcare System, Jamaica Plain, Boston, Massachusetts.,Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts
| | - Karina Furlan
- Department of Pathology, Rush University, Chicago, Illinois
| | - Alexandra Weil
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Kaitlyn Sacotte
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Jake M Lazaroff
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Katherine Lin
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Diana Aranzazu
- Skin Laser & Surgery Specialists of New York and New Jersey, New York
| | - Mathew M Avram
- Department of Dermatology, Harvard Medical School, Boston, Massachusetts.,Dermatology Cosmetic and Laser Center, Massachusetts General Hospital, Harvard Medical School, Boston
| | - Ashley Bell
- Advanced Skin Research Center, Omaha, Nebraska
| | - Todd V Cartee
- Department of Dermatology, Penn State Health Milton S. Hershey Medical Center, Hershey
| | - Alex Cazzaniga
- Skin Research Institute and Skin Associates of South Florida, Coral Gables
| | - Anne Chapas
- Union Square Laser Dermatology, New York, New York
| | | | | | - Catherine M DiGiorgio
- Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston.,Krauss Dermatology, Wellesley Hills, Massachusetts
| | - Jeffrey S Dover
- SkinCare Physicians, Chestnut Hill, Massachusetts.,Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.,Department of Dermatology, Brown Medical School, Providence, Rhode Island
| | - David J Goldberg
- Skin Laser & Surgery Specialists of New York and New Jersey, New York.,Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.,Division of Dermatology, University of Medicine and Dentistry of New Jersey-Rutgers School of Medicine, Newark.,Fordham University Law School, New York, New York
| | - Mitchel P Goldman
- Department of Dermatology, University of California, San Diego.,Goldman, Butterwick, Groff, Fabi and Wu Cosmetic Laser Dermatology, A West Dermatology Company, San Diego, California
| | - Jeremy B Green
- Skin Research Institute and Skin Associates of South Florida, Coral Gables
| | - Charmaine L Griffin
- Laser and Cosmetic Center/McDaniel Institute of Anti-Aging Research, Virginia Beach
| | - Adele D Haimovic
- Lance H. Brown, MD, PLLC, New York, New York.,Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York
| | - Amelia K Hausauer
- Aesthetx, Campbell, California.,Skin Care and Laser Physicians of Beverly Hills, Los Angeles, California
| | | | - Sarah Hsu
- Maryland Laser Skin and Vein Institute, Hunt Valley
| | - Omer Ibrahim
- Chicago Cosmetic Surgery and Dermatology, Chicago, Illinois
| | - Derek H Jones
- Skin Care and Laser Physicians of Beverly Hills, Los Angeles, California
| | - Joely Kaufman
- Skin Research Institute and Skin Associates of South Florida, Coral Gables
| | - Suzanne L Kilmer
- Laser & Skin Surgery Medical Group, Inc, Sacramento, California.,Department of Dermatology, University of California, Davis, School of Medicine, Oakland
| | | | - David H McDaniel
- Laser and Cosmetic Center/McDaniel Institute of Anti-Aging Research, Virginia Beach.,Department of Biological Sciences, Old Dominion University, Norfolk, Virginia.,Hampton University Skin of Color Research Institute, Hampton, Virginia.,School of Science, Hampton University, Hampton, Virginia
| | | | - Elizabeth Tanzi
- Capital Laser and Skin Care, Chevy Chase, Maryland.,Department of Dermatology, George Washington University, Washington, DC
| | - Eduardo T Weiss
- Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida.,Hollywood Dermatology and Cosmetic Surgery Specialist, Hollywood, Florida
| | - Robert A Weiss
- Skin Care and Laser Physicians of Beverly Hills, Los Angeles, California
| | - Douglas Wu
- Goldman, Butterwick, Groff, Fabi and Wu Cosmetic Laser Dermatology, A West Dermatology Company, San Diego, California
| | - Emily Poon
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Murad Alam
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.,Department of Otolaryngology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.,Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| |
Collapse
|
49
|
Zero O, Kempner M, Hsu S, Haleem H, Tobin-Tyler E, Toll E. Addressing Global Human Rights Violations in Rhode Island: The Brown Human Rights Asylum Clinic. R I Med J (2013) 2019; 102:17-20. [PMID: 31480813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
The Brown Human Rights Asylum Clinic (BHRAC) is a medical student-led organization affiliated with Physicians for Human Rights that collaborates with medical and mental health clinicians, lawyers, and community organizations to provide pro bono medical affidavits to undocumented individuals seeking legal status in the United States. Affidavits can document and corroborate the physical and psychological evidence of trauma alleged by asylum seekers, leading to better legal outcomes. This article describes our innovative program, partnerships, and workflow, as well as demographics and statistics from our past seven years of operation. Since its founding in 2013, BHRAC has conducted 55 medical evaluations, the majority involving Spanish-speaking female-identifying individuals from Guatemala, El Salvador, and the Dominican Republic. Thirteen individuals have been granted legal status, one individual was denied status, and the rest of the cases are pending. BHRAC has experienced a marked increase in affidavit requests. This paper serves as a call to action for medical professionals to become involved in this work.
Collapse
Affiliation(s)
- Odette Zero
- Candidate, Primary Care-Population Medicine Program, Alpert Medical School of Brown University
| | - Marga Kempner
- Candidate, Alpert Medical School of Brown University
| | - Sarah Hsu
- Candidate, Primary Care-Population Medicine Program, Alpert Medical School of Brown University
| | - Heba Haleem
- Candidate, Alpert Medical School of Brown University
| | - Elizabeth Tobin-Tyler
- Assistant Professor of Family Medicine and Medical Science, Alpert Medical School of Brown University; Assistant Professor of Health Services, Policy and Practice, Brown University School of Public Health
| | - Elizabeth Toll
- Clinical Associate Professor of Pediatrics and Medicine, Alpert Medical School of Brown University
| |
Collapse
|
50
|
Yalcin Y, Muslem R, Veen K, Tedford R, Tomashitis B, Najam YA, Kilic A, Houston B, Brugts J, Constantinescu A, Manintveld O, Hsu S, Bogers A, Caliskan K. Impact of Left Ventricular Assist Device Placement on Chronic Kidney Diseases: A Multicenter Longitudinal Study. J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|